Fed. Circ. To Revisit Ariad, Lilly IP Dispute En Banc

Law360, New York (August 24, 2009, 2:56 PM EDT) -- A federal appeals court has granted Ariad Pharmaceuticals Inc.'s request for an en banc rehearing in its patent infringement suit against Eli Lilly & Co. over the drugs Evista and Xigris, vacating an April decision that found Ariad's patent invalid.

The U.S. Court of Appeals for the Federal Circuit on Friday said it would rehear Lilly's appeal of a lower court's judgment holding the pharmaceutical giant liable for infringing U.S. Patent Number 6,410,516, which covers methods of treating human disease by regulating natural cell-signaling activity....
To view the full article, register now.